A comprehensive view of Illnesses/Symptoms/Conditions. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Fitch: Covid-19 vaccine sales saw strong start to 2022, with Pfizer and Moderna posting stronger-than-expected Q1 sales; 2022 sales could be comparable to significant 2021 numbers, but estimates for 2023 should see more pronounced decrease in market size

Bill Gates sees 50% chance of new pandemic in next 20 years, says mortality rate raised to 5% could be 'end of society' versus COVID's 0.2% mortality rate; solution to prevent next pandemic would cost US$1B/year, compared to US$14B lost to pandemic so far

Cantor Fitzgerald expects sales of COVID vaccines and therapeutics to plateau on slowing demand, adequate supplies in many nations; meanwhile, people have opted for boosters at lower rate than they received initial vaccine regimens, further hurting demand

Tech vs. Trees: 3D-printed wooden beehives aim to support bee populations, UK studio reimagines COVID-19 rapid test as paper-based and biodegradable, student spending on print textbooks down as much as 69% in last decade

BofA initiates Novavax with underperform rating, noting firm’s sales projections for COVID vaccine are below consensus given bearish outlook on continued booster use, uncertain benefits as a differentiated option, drop in immunity against new variants

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count